Stephen Hall - BG Medicine CFO
| BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
CFO
Mr. Stephen P. Hall is Chief Financial Officer, Executive Vice President, Treasurer of BG Medicine, Inc., since December 3, 2013. Mr. Hall served as Vice President of Finance and Chief Accounting Officer of Stemline Therapeutics, Inc., a public biopharmaceutical company, from October 2012 to November 2013. Previously, Mr. Hall was founder and managing director of Deimos Consulting, LLC, a management consulting firm specializing in life sciences. Mr. Hall has also served as Senior Vice President, Chief Financial Officer, Chief Compliance Officer and Treasurer of Orthocon, Inc., a New Yorkbased medical products company, from October 2009 to October 2010. Prior to this, Mr. Hall served as Senior Vice President, Chief Financial Officer and Treasurer of Helicos BioSciences, a public life science company, from May 2008 until August 2009. Mr. Hall previously served as Senior Vice President and Chief Financial Officer of TriPath Imaging, Inc., a public cancer diagnostics company, from September 2001 to December 2006, when it was acquired by Becton, Dickinson and Company, at which time Mr. Hall continued to serve as Senior Advisor to Becton, Dickinson and Company from December 2006 to June 2007. Mr. Hall served as Chief Financial Officer of Colorado Medtech, Inc., a public medical products and services company, from September 1999 until August 2001 and also served as President of its Imaging and Power System Division. From September 1990 to August 1993, he served as Chief Financial Officer for BioTechnica International, Inc., a publiclyheld agricultural products company since 2013.
| Age | 72 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 781 890 1199 |
| Web | https://www.bg-medicine.com |
BG Medicine Management Efficiency
The company has return on total asset (ROA) of (0.7595) % which means that it has lost $0.7595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.0264) %, meaning that it created substantial loss on money invested by shareholders. BG Medicine's management efficiency ratios could be used to measure how well BG Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CFO Age | ||
| Don Desjarlais | Innovative Eyewear | 53 | |
| David Naim | Microbot Medical | 48 | |
Management Performance
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 |
BG Medicine Leadership Team
Elected by the shareholders, the BG Medicine's board of directors comprises two types of representatives: BG Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGMD. The board's role is to monitor BG Medicine's management team and ensure that shareholders' interests are well served. BG Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BG Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Connor, Director | ||
| Harry Wilcox, Director | ||
| Stelios Papadopoulos, Independent Director | ||
| Aram Adourian, Chief Scientific Officer and Sr. VP | ||
| Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer | ||
| Jeffrey Luber, Director | ||
| Paul Sohmer, President CEO, Director | ||
| Noubar Afeyan, Founder | ||
| James OConnor, Independent Director |
BGMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BG Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.86) % | ||||
| Current Valuation | 545.97 K | ||||
| Shares Outstanding | 11.37 M | ||||
| Number Of Shares Shorted | 630.05 K | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.35 X | ||||
| Revenue | 1.57 M | ||||
| Gross Profit | 1.06 M |
Pair Trading with BG Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BG Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BG Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against BGMD Pink Sheet
| 0.56 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.43 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to BG Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BG Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BG Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BG Medicine to buy it.
The correlation of BG Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BG Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BG Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BG Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |